CL2022003041A1 - Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 - Google Patents
Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2Info
- Publication number
- CL2022003041A1 CL2022003041A1 CL2022003041A CL2022003041A CL2022003041A1 CL 2022003041 A1 CL2022003041 A1 CL 2022003041A1 CL 2022003041 A CL2022003041 A CL 2022003041A CL 2022003041 A CL2022003041 A CL 2022003041A CL 2022003041 A1 CL2022003041 A1 CL 2022003041A1
- Authority
- CL
- Chile
- Prior art keywords
- agonists
- compounds
- heterocyclic compounds
- myeloid cells
- receptor expressed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019768P | 2020-05-04 | 2020-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003041A1 true CL2022003041A1 (es) | 2023-07-14 |
Family
ID=78468393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003041A CL2022003041A1 (es) | 2020-05-04 | 2022-11-03 | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US12252489B2 (https=) |
| EP (1) | EP4146220B1 (https=) |
| JP (2) | JP7741100B2 (https=) |
| KR (1) | KR20230020983A (https=) |
| CN (1) | CN116322696A (https=) |
| AU (1) | AU2021267161A1 (https=) |
| BR (1) | BR112022022338A2 (https=) |
| CA (1) | CA3182541A1 (https=) |
| CL (1) | CL2022003041A1 (https=) |
| CO (1) | CO2022015927A2 (https=) |
| CR (1) | CR20220559A (https=) |
| CU (1) | CU20220065A7 (https=) |
| EC (1) | ECSP22089520A (https=) |
| IL (2) | IL325121A (https=) |
| JO (1) | JOP20220295A1 (https=) |
| MX (1) | MX2022013838A (https=) |
| PE (1) | PE20230609A1 (https=) |
| PH (1) | PH12022552933A1 (https=) |
| WO (1) | WO2021226135A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| WO2023086800A1 (en) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| AR127621A1 (es) * | 2021-11-09 | 2024-02-14 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso |
| EP4430022A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE |
| WO2024008722A2 (en) * | 2022-07-04 | 2024-01-11 | Muna Therapeutics Aps | Trem2 modulators |
| TW202517639A (zh) | 2023-07-17 | 2025-05-01 | 丹麥商穆納醫療有限責任公司 | Trem2調節劑 |
| WO2025136898A1 (en) * | 2023-12-18 | 2025-06-26 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
| TW202535410A (zh) | 2024-01-04 | 2025-09-16 | 丹麥商穆納醫療有限責任公司 | Ｔｒｅｍ２調節劑 |
| WO2025146477A1 (en) | 2024-01-04 | 2025-07-10 | Muna Therapeutics Aps | 2-azetidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives derivatives as trem2 modulators for the treatment of neurodegenerative diseases |
| WO2025176753A1 (en) * | 2024-02-22 | 2025-08-28 | F. Hoffmann-La Roche Ag | Condensed pyrimidine derivates als trem2 agonists |
| WO2025176748A1 (en) * | 2024-02-22 | 2025-08-28 | F. Hoffmann-La Roche Ag | Condensed pyrazines or pyrimidines als trem2 agoonists |
| WO2025191114A1 (en) * | 2024-03-14 | 2025-09-18 | Muna Therapeutics Aps | Trem2 modulators |
| WO2026077861A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026077862A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US2963481A (en) | 1959-11-27 | 1960-12-06 | Smith Kline French Lab | 6-pteridinecarboxylic acid esters |
| US3712892A (en) | 1969-08-02 | 1973-01-23 | Sumitomo Chemical Co | Quinazolinone derivatives |
| JPH05170744A (ja) | 1991-12-25 | 1993-07-09 | Toray Dow Corning Silicone Co Ltd | 含窒素芳香族複素環式化合物のアルキル化方法 |
| EP0743855A1 (en) | 1994-01-03 | 1996-11-27 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| DK1028950T3 (da) | 1997-10-28 | 2003-09-01 | Warner Lambert Co | 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| JP2004521892A (ja) | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| JP2003005355A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はｘ線用ネガ型レジスト組成物 |
| JP4690043B2 (ja) | 2002-10-04 | 2011-06-01 | プラナ バイオテクノロジー リミティッド | 神経に対し活性な化合物 |
| GB0229281D0 (en) | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| PL1673092T3 (pl) | 2003-10-17 | 2008-01-31 | 4 Aza Ip Nv | Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu |
| JP2007510642A (ja) | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| RU2358969C2 (ru) | 2004-02-13 | 2009-06-20 | Баниу Фармасьютикал Ко., Лтд. | Конденсированное 4-оксопиримидиновое производное |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| NZ551004A (en) | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| KR100659088B1 (ko) | 2005-07-15 | 2006-12-21 | 삼성에스디아이 주식회사 | 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자 |
| JP2009509963A (ja) | 2005-09-23 | 2009-03-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP2009528387A (ja) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン |
| US7855194B2 (en) | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| WO2008003149A2 (en) | 2006-07-06 | 2008-01-10 | Gilead Sciences , Inc. | Substituted pteridines for the treatment and prevention of viral infections |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| US8048894B2 (en) | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| MX2010004074A (es) | 2007-10-15 | 2010-07-02 | Astrazeneca Ab | Combinacion 059. |
| TW200938542A (en) * | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2009100406A2 (en) | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
| US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
| US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010042925A2 (en) | 2008-10-10 | 2010-04-15 | Vm Discovery Inc. | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US8722692B2 (en) * | 2009-07-30 | 2014-05-13 | Jianwei Che | Compounds and compositions as Syk kinase inhibitors |
| WO2011014039A1 (en) | 2009-07-31 | 2011-02-03 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
| US20110124597A1 (en) | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| MX2012004846A (es) | 2009-10-29 | 2012-10-05 | Genosco | Inhibidores de cinasa. |
| BR112012022868A2 (pt) | 2010-03-16 | 2018-06-05 | Merck Patent Gmbh | morfolinilquinazolinas |
| US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
| KR101497124B1 (ko) | 2011-11-28 | 2015-03-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치 |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| CN103374021B (zh) | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
| EP2900639B1 (en) * | 2012-09-27 | 2017-08-16 | Portola Pharmaceuticals, Inc. | Bicyclic dihydropyridone kinase inhibitors |
| WO2014146249A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| WO2015002729A2 (en) * | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Cell stabilization |
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| ES2750236T3 (es) | 2013-12-09 | 2020-03-25 | UCB Biopharma SRL | Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF |
| KR20150080966A (ko) | 2014-01-02 | 2015-07-13 | 최돈수 | 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료 |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| KR20160060572A (ko) | 2014-11-19 | 2016-05-30 | 주식회사 엠비케이 | 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기 |
| RU2717665C2 (ru) | 2015-04-15 | 2020-03-24 | Ф. Хоффманн-Ля Рош Аг | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
| US10403826B2 (en) | 2015-05-07 | 2019-09-03 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP3335254B1 (de) | 2015-08-11 | 2020-04-08 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10573692B2 (en) | 2016-04-06 | 2020-02-25 | Samsung Display Co., Ltd. | Organic light-emitting device having a sealing thin film encapsulation portion |
| PL3442947T3 (pl) | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| US11283028B2 (en) | 2016-10-05 | 2022-03-22 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent compound and organic electroluminescent device comprising the same |
| CN109790183A (zh) | 2016-12-13 | 2019-05-21 | 广州华睿光电材料有限公司 | 金属有机配合物及其应用、混合物、有机电子器件 |
| TW201843143A (zh) | 2017-03-13 | 2018-12-16 | 德商麥克專利有限公司 | 含有芳基胺結構之化合物 |
| WO2018169352A1 (en) | 2017-03-16 | 2018-09-20 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent device |
| KR102335935B1 (ko) | 2017-03-22 | 2021-12-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| US20200113901A1 (en) | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| KR102389204B1 (ko) | 2017-04-18 | 2022-04-21 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| WO2018204765A1 (en) | 2017-05-05 | 2018-11-08 | Pairnomix, Llc | Methods of treating epilepsy and kcnq2 related conditions |
| WO2018204764A1 (en) * | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| CN110996945A (zh) | 2017-06-13 | 2020-04-10 | 联邦科学技术研究组织 | 抗病毒药物 |
| EP3689866A4 (en) | 2017-09-26 | 2021-07-07 | Nippon Soda Co., Ltd. | QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE |
| AU2018353139A1 (en) | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
| JP2021500326A (ja) | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法 |
| CN108484680B (zh) | 2018-01-31 | 2020-12-11 | 马鞍山南京大学高新技术研究院 | 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物 |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US12453279B2 (en) | 2018-08-22 | 2025-10-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| CN109265457A (zh) | 2018-11-01 | 2019-01-25 | 中国药科大学 | 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法 |
| WO2020231739A2 (en) | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
| CN110283171A (zh) | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
| US11820783B2 (en) | 2019-09-06 | 2023-11-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| BR112022022184A2 (pt) | 2020-05-04 | 2023-01-17 | Takeda Pharmaceuticals Co | Derivados de n-(piperidin-4-il)benzamida agindo luminalmente |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| IL297864A (en) | 2020-05-04 | 2023-01-01 | Adama Makhteshim Ltd | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof |
| CN111454265B (zh) | 2020-05-07 | 2021-08-24 | 宁波卢米蓝新材料有限公司 | 一种稠杂环化合物及其制备方法和应用 |
| CA3244298A1 (en) | 2022-01-11 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE |
-
2021
- 2021-05-04 JP JP2022567488A patent/JP7741100B2/ja active Active
- 2021-05-04 CU CU2022000065A patent/CU20220065A7/es unknown
- 2021-05-04 CA CA3182541A patent/CA3182541A1/en active Pending
- 2021-05-04 PH PH1/2022/552933A patent/PH12022552933A1/en unknown
- 2021-05-04 IL IL325121A patent/IL325121A/en unknown
- 2021-05-04 CN CN202180045770.6A patent/CN116322696A/zh active Pending
- 2021-05-04 WO PCT/US2021/030719 patent/WO2021226135A1/en not_active Ceased
- 2021-05-04 CR CR20220559A patent/CR20220559A/es unknown
- 2021-05-04 BR BR112022022338A patent/BR112022022338A2/pt unknown
- 2021-05-04 IL IL297845A patent/IL297845B1/en unknown
- 2021-05-04 AU AU2021267161A patent/AU2021267161A1/en active Pending
- 2021-05-04 KR KR1020227042514A patent/KR20230020983A/ko active Pending
- 2021-05-04 EP EP21799590.1A patent/EP4146220B1/en active Active
- 2021-05-04 US US17/923,160 patent/US12252489B2/en active Active
- 2021-05-04 PE PE2022002572A patent/PE20230609A1/es unknown
- 2021-05-04 MX MX2022013838A patent/MX2022013838A/es unknown
-
2022
- 2022-11-02 JO JOJO/P/2022/0295A patent/JOP20220295A1/ar unknown
- 2022-11-03 CL CL2022003041A patent/CL2022003041A1/es unknown
- 2022-11-04 CO CONC2022/0015927A patent/CO2022015927A2/es unknown
- 2022-11-21 EC ECSENADI202289520A patent/ECSP22089520A/es unknown
- 2022-11-30 US US18/072,497 patent/US11718617B2/en active Active
-
2023
- 2023-04-28 US US18/309,281 patent/US12319691B2/en active Active
-
2025
- 2025-02-21 US US19/060,264 patent/US20250388574A1/en active Pending
- 2025-09-04 JP JP2025146675A patent/JP2025179173A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022013838A (es) | 2023-02-22 |
| PE20230609A1 (es) | 2023-04-13 |
| PH12022552933A1 (en) | 2024-02-12 |
| JP7741100B2 (ja) | 2025-09-17 |
| US12319691B2 (en) | 2025-06-03 |
| CN116322696A (zh) | 2023-06-23 |
| AU2021267161A1 (en) | 2022-12-08 |
| US20230144581A1 (en) | 2023-05-11 |
| CO2022015927A2 (es) | 2023-01-26 |
| JOP20220295A1 (ar) | 2022-11-02 |
| CA3182541A1 (en) | 2021-11-11 |
| ECSP22089520A (es) | 2023-02-28 |
| EP4146220B1 (en) | 2026-02-18 |
| KR20230020983A (ko) | 2023-02-13 |
| US20240190863A1 (en) | 2024-06-13 |
| IL297845A (en) | 2023-01-01 |
| BR112022022338A2 (pt) | 2023-01-10 |
| US20240124446A1 (en) | 2024-04-18 |
| JP2025179173A (ja) | 2025-12-09 |
| CU20220065A7 (es) | 2023-06-13 |
| IL297845B1 (en) | 2026-01-01 |
| US12252489B2 (en) | 2025-03-18 |
| JP2023524806A (ja) | 2023-06-13 |
| US11718617B2 (en) | 2023-08-08 |
| WO2021226135A1 (en) | 2021-11-11 |
| EP4146220A4 (en) | 2024-05-29 |
| IL325121A (en) | 2026-02-01 |
| EP4146220A1 (en) | 2023-03-15 |
| CR20220559A (es) | 2023-08-18 |
| EP4146220C0 (en) | 2026-02-18 |
| US20250388574A1 (en) | 2025-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003047A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CL2022003041A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| UY31063A1 (es) | Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones. | |
| AR134657A1 (es) | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso | |
| CU23824A3 (es) | Compuestos tricíclicos y sus composiciones | |
| MX2022009528A (es) | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. | |
| UY36126A (es) | ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?. | |
| ECSP11011470A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| NI201000090A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
| CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
| AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CL2025000299A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarínico. | |
| MX2024009161A (es) | Compuestos de pirrolidina. | |
| ECSP11010807A (es) | Sales de los compuestos del inhibidor de vih | |
| CL2025003186A1 (es) | Moduladores de nk3 y usos de los mismos. | |
| AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
| CO2025017454A2 (es) | Sales cristalinas o formas amorfas de 2-((1h-pirazol-3-il)metil)-6-((6-aminopiridin-2-il)metil)-4-metil-4,6-dihidro-5h-thiazolo[5',4':4,5]pirrolo[2,3-d]piridazin-5-ona | |
| AR134656A1 (es) | Compuestos de piridinona heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
| AR127622A1 (es) | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso | |
| AR068978A1 (es) | N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas | |
| UY31812A (es) | Derivados de cinolina como inhibidores de csf-1 |